Evidence map›Paper›PMID 39260365›Full record

ArticleCell reports methods2024

An improved approach to generate IL-15

An-Ping Chen, Peng Gao, Liang Lin, Preeti Ashok, Hongzhi He, Chao Ma, David Li Zou, Vincent Allain, Alex Boyne, Alexandre Juillerat and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports methods, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Engineering Immune Cell to Counteract Aging and Aging-Associated Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026
    Review
  2. Challenges and opportunities of human iPSC-derived NK as "Off-the-shelf" cellular therapies.Journal of experimental & clinical cancer research : CR · 2025
    Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

An-Ping ChenCytovia Therapeutics, Inc., Natick, MA, USA. Electronic address: anping.chen@cytoviatx.com.
Peng GaoCytovia Therapeutics, Inc., Natick, MA, USA.
Liang LinCytovia Therapeutics, Inc., Natick, MA, USA.
Preeti AshokCytovia Therapeutics, Inc., Natick, MA, USA.
Hongzhi HeCytovia Therapeutics, Inc., Natick, MA, USA.
Chao MaCytovia Therapeutics, Inc., Natick, MA, USA.
David Li ZouCytovia Therapeutics, Inc., Natick, MA, USA.
Vincent AllainGladstone-University of California, San Francisco Institute of Genomic Immunology, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA; Université Paris Cité, INSERM UMR976, Hôpital Saint-Louis, Paris, France.
Alex BoyneCellectis Inc, New York, NY, USA.
Alexandre JuilleratCellectis Inc, New York, NY, USA.
Philippe DuchateauCellectis, Paris, France.
Armin RathCytovia Therapeutics, Inc., Aventura, FL, USA.
Daniel TeperCytovia Therapeutics, Inc., Aventura, FL, USA.
Antonio ArulanandamCytovia Therapeutics, Inc., Natick, MA, USA.
Hao-Ming ChangCytovia Therapeutics, Inc., Natick, MA, USA.
Justin EyquemGladstone-University of California, San Francisco Institute of Genomic Immunology, San Francisco, CA, USA; Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Wei LiCytovia Therapeutics, Inc., Natick, MA, USA. Electronic address: wei.li@cytoviatx.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present a TALEN-based workflow to generate and maintain dual-edited (IL-15

Indexed as

Induced Pluripotent Stem CellsInterleukin-15Killer Cells, NaturalReceptor, Transforming Growth Factor-beta Type IICell DifferentiationGene EditingHumansTranscription Activator-Like Effector NucleasesIL15 protein, humanInterleukin-15Receptor, Transforming Growth Factor-beta Type IITGFBR2 protein, humanTranscription Activator-Like Effector Nucleasesanti-tumorB2Mbeta-2-microglobulinCP: cancer biologygene editingGUIDE-seqhuman induced pluripotent stem cellsinterleukin-15iPSC-derived cell therapiesiPSCsnatural killer cellsTALENTGFβR2

Identifiers

PMID39260365
PMCPMC11440057

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.